On Invalid Date, Taysha Gene Therapies (NASDAQ: TSHA) reported Q4 2023 earnings per share (EPS) of $0.92, up 192.93% year over year. Total Taysha Gene Therapies earnings for the quarter were $47.74 million. In the same quarter last year, Taysha Gene Therapies's earnings per share (EPS) was -$0.99.
As of Q2 2024, Taysha Gene Therapies's earnings has grown year over year. Taysha Gene Therapies's earnings in the past year totalled -$111.57 million.
What is TSHA's earnings date?
Taysha Gene Therapies's earnings date is Invalid Date. Add TSHA to your watchlist to be reminded of TSHA's next earnings announcement.
What was TSHA's revenue last quarter?
On Invalid Date, Taysha Gene Therapies (NASDAQ: TSHA) reported Q4 2023 revenue of $3.60 million up 44.04% year over year. In the same quarter last year, Taysha Gene Therapies's revenue was $2.50 million.
What was TSHA's revenue growth in the past year?
As of Q2 2024, Taysha Gene Therapies's revenue has grown 517.55% year over year. This is 368.25 percentage points higher than the US Biotechnology industry revenue growth rate of 149.3%. Taysha Gene Therapies's revenue in the past year totalled $15.45 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.